Novartis to shut Horsham site


With the closure of the Horsham site Novartis only has one remaining R&D site in the UK © Novartis

Swiss pharmaceutical firm Novartis has announced that it plans to close its Horsham site in Sussex, with up to 371 jobs affected. Currently the facility is involved in respiratory research and is one of the few remaining Novartis sites performing research and development in the UK. Last year, the firm slammed the UK for the high cost of conducting clinical trials in the country, warning that business would leave unless more incentives were introduced to encourage firms to carry out R&D. The restructure is intended to concentrate all R&D in three major hubs in Europe, the US and China.

The Horsham site was downsized back in 2011, when manufacturing and global development at the site were closed and gastrointestinal research was moved to Basel, Switzerland. The 2011 job losses at Horsham preceded a much larger swathe of job cuts at Novartis, with over 2000 jobs cut in Switzerland and the US in an attempt to improve productivity and absorb pricing pressures in Europe.

In a statement the company explained that it ‘continually evaluates its resource allocation to ensure that the organisation is highly flexible and able to proactively adapt to external challenges to best meet the needs of patients and customers. Our pipeline and future potential growth are strong. However, we face challenges in today’s industry.’

The Novartis statement added that the decision will be subject to an employee consultation process and final approval by the company’s UK board. After the closure of Horsham the company will continue to operate a number of UK manufacturing sites, as well as a team in Sittingbourne, Kent, that develops patient diagnostic tests. 


Related Content

Weathering the storm

6 January 2014 Business

news image

Pharmaceutical industry roundup 2013

Novartis and DSM trim jobs

24 January 2014 Business

news image

Novartis to close US manufacturing site, both companies restructuring Swiss operations

Most Read

Antimicrobial resistance will kill 300 million by 2050 without action

16 December 2014 News and Analysis

news image

UK report says resistance will cost global economy $100 trillion

Cutting edge chemistry in 2014

10 December 2014 Research

news image

We take a look back at the year's most interesting chemical science stories

Most Commented

A bad business

19 December 2014 Critical Point

news image

Targets and assessments can boost productivity at universities – but only if they do not stifle creativity and alienate the...

Unusual 2D silica allotrope predicted

25 June 2014 Research

news image

Simulations say graphene-like silica would become thicker when stretched